On September 10, Cooper fell 15.28% in pre-market trading, trading at $53.95/share, with turnover of $46,400. The decline was triggered by the company's fiscal Q3 earnings report, which showed revenue missing Wall Street estimates alongside a significant downward revision to full-year guidance.

Cooper reported fiscal Q3 revenue of $1.066 billion, falling short of the analyst consensus estimate of $1.098 billion. While adjusted EPS of $1.15 narrowly beat the $1.12 estimate, the top-line miss overshadowed the bottom-line beat. More critically, the company lowered its full-year fiscal 2026 revenue guidance to $4.23 billion–$4.25 billion, well below the prior range of $4.29 billion–$4.32 billion and the FactSet consensus of $4.31 billion. Full-year adjusted EPS guidance was also cut to $4.51–$4.55 from $4.58–$4.66. Interim financials revealed net income of just $52.9 million, down 72.45% year-over-year. The company simultaneously announced it would retain CooperSurgical after a strategic review, expanded its share buyback program to $3 billion, and reaffirmed cumulative free cash flow exceeding $2.2 billion over fiscal 2026–2028, but these measures failed to offset near-term earnings deterioration concerns.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)